Lutetium Vipivotide Tetraxetan
Metastatic Castration-resistant Prostate Cancer
Novartis PharmaceuticalsradiopharmaceuticalActive
D
28/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 65/ 100
Competitive context
251 Active assets in the Metastatic Castration-resistant Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BBB |
Fluciclovine VA Greater Los Angeles Healthcare System | Phase 4 | BBB |
LEUPROLIDE Mayo Clinic | Phase 4 | BBB |
Abiraterone Acetate Mayo Clinic | Phase 4 | BB |
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →